Study to Assess Absolute Bioavailability (ABA) of TAK-906 and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of [14C]-TAK-906 in Healthy Male Participants
Condition: Healthy Volunteers
Intervention: TAK-906 Oral Capsule; [14C]-TAK-906 Intravenous Infusion; [14C]-TAK-906 Oral Solution
Intervention description: TAK-906 capsule.; [14C]-TAK-906 intravenous infusion.; [14C]-TAK-906 oral solution.
Phase: Phase 1
Study type: Interventional
Primary purpose: Other
Intervention model: Single Group Assignment
Masking: None (Open Label)
Enrollment: 6.0
Sex: Male
Minimum age: 19 Years
Maximum age: 55 Years
Healthy volunteers: Accepts Healthy Volunteers
Keywords: Drug Therapy

Summary:

      The purpose of this study is to determine ABA of TAK-906 following single oral (capsule)
      administration of 50 milligram (mg) of TAK-906 and single intravenous (IV) microtracer dose
      administration of 100 microgram (μg) (approximately 1 microcurie [μCi]) of [14C]-TAK-906 in
      Period 1 (ABA), and to determine the mass balance of TAK-906 in urine and feces following a
      single oral (solution) administration of 50 mg (approximately 100 μCi) of [14C]-TAK-906 in
      Period 2 (absorption, distribution, metabolism, and elimination [ADME]).
    

Eligibility criteria:

        Inclusion Criteria:

          1. Continuous non-smoker who has not used nicotine-containing products for at least 3
             months prior to the first dosing and throughout the study.

          2. Body mass index (BMI) greater than or equal to (>=) 18.0 and less than (˂) 30.0
             kilogram per square meter (kg/m^2) at screening.

        Exclusion Criteria:

          1. QT interval corrected for heart rate using Fridericia's formula (QTcF) interval is
             greater than (>) 450 millisecond (msec) or Electrocardiogram (ECG) findings are deemed
             abnormal with clinical significance by the Investigator or designee at screening.

          2. Estimated creatinine clearance less than (<) 90 milliliter per minute (mL/min) at
             screening.

          3. Has tattoo(s) or scarring at or near the site of intravenous (IV) infusion or any
             other condition which may interfere with infusion site examination, in the opinion of
             the Investigator.

          4. Has infrequent bowel movements (less than approximately once per day) within 30 days
             prior to first dosing.

          5. Has received radiolabeled substances or has been exposed to radiation sources within
             12 months of first dosing or is likely to receive radiation exposure or radioisotopes
             within 12 months of last dosing such that participation in this study would increase
             their total exposure beyond the recommended levels considered safe (that is weighted
             annual limit recommended by the International Commission on Radiological Protection
             [ICRP] of 3000 milli roentgen equivalent man [mrem]).

          6. Has been on a diet incompatible with the on-study diet, in the opinion of the
             Investigator or designee, within the 30 days prior to the first dosing and throughout
             the study.

          7. Donation of blood or significant blood loss within 56 days prior to the first dosing.

          8. Plasma donation within 7 days prior to the first dosing.

          9. Unable to refrain from or anticipates the use of:

               -  Any drug, including prescription and non-prescription medications, herbal
                  remedies, or vitamin supplements within 14 days prior to the first dosing and
                  throughout the study. Acetaminophen (up to 2 g per 24 hour period) and Milk of
                  Magnesia® (that is, magnesium hydroxide [less than or equal to (<=) 60 mL per day
                  after Day 3 in Period 1 and after Day 8 in Period 2]) may be permitted during the
                  study, only after dosing, if necessary to treat adverse events (AEs). Additional
                  administration of Milk of Magnesia® may be administered on other days at
                  discretion of the Investigator.

               -  Any drugs known to significantly affect the absorption, distribution, metabolism
                  or elimination of TAK-906 within 28 days prior to the first dosing and throughout
                  the study. Appropriate sources (example, Flockhart Table TM) will be consulted to
                  confirm lack of PK/pharmacodynamics interaction with study drug.